KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Convertible Debt: 2015

Historic Convertible Debt for CRISPR Therapeutics AG (CRSP) over the last 1 years, with Dec 2015 value amounting to $38.3 million.

  • CRISPR Therapeutics AG's Convertible Debt was N/A to $38.3 million in Q4 2015 from the same period last year, while for Dec 2015 it was $38.3 million, marking a year-over-year change of. This contributed to the annual value of $38.3 million for FY2015, which is N/A change from last year.
  • According to the latest figures from FY2015, CRISPR Therapeutics AG's Convertible Debt is $38.3 million.
  • In the past 5 years, CRISPR Therapeutics AG's Convertible Debt ranged from a high of $38.3 million in FY2015 and a low of $38.3 million during FY2015.
  • Over the past 1 years, CRISPR Therapeutics AG's median Convertible Debt value was $38.3 million (recorded in 2015), while the average stood at $38.3 million.